Multi-omics analyses of CD276 in pan-cancer reveals its clinical prognostic value in glioblastoma and other major cancer types

BMC Cancer

Research

Weihua Hu¹  Wulong Liang¹  Shaolong Zhou¹  Zimin Shi²  Zhe Xing²  Xinjun Wang²  Xuyang Guo²  Yiran Tao²  Lirui Dai² 

[1] Department of Neurosurgery, The Fifth Affiliated Hospital of Zhengzhou University, Zhengzhou University, 450052, Zhengzhou, China;Henan International Joint Laboratory of Glioma Metabolism and Microenvironment Research, Zhengzhou, Henan, China;Department of Neurosurgery, The Fifth Affiliated Hospital of Zhengzhou University, Zhengzhou University, 450052, Zhengzhou, China;Institute of Neuroscience, Zhengzhou University, 450052, Zhengzhou, China;Henan International Joint Laboratory of Glioma Metabolism and Microenvironment Research, Zhengzhou, Henan, China;

关键词: Pan-cancer;    Single-cell analysis;    Bioinformatics;    Immune microenvironment;    CD276;    Immune checkpoints;    Glioblastoma;   

DOI  :  10.1186/s12885-023-10575-1

 received in 2022-10-19, accepted in 2023-01-23,  发布年份 2023

来源: Springer

【 摘 要 】

BackgroundCD276 (also known as B7-H3) is one of the most important immune checkpoints of the CD28 and B7 superfamily, and its abnormal expression is closely associated with various types of cancer. It has been shown that CD276 is able to inhibit the function of T cells, and that this gene may potentially be a promising immunotherapy target for different types of cancer.MethodsSince few systematic studies have been published on the role of CD276 in cancer to date, the present study has employed single-cell sequencing and bioinformatics methods to analyze the expression patterns, clinical significance, prognostic value, epigenetic alterations, DNA methylation level, tumor immune cell infiltration and immune functions of CD276 in different types of cancer. In order to analyze the potential underlying mechanism of CD276 in glioblastoma (GBM) to assess its prognostic value, the LinkedOmics database was used to explore the biological function and co-expression pattern of CD276 in GBM, and Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses were performed. In addition, a simple validation of the above analyses was performed using reverse transcription-quantitative (RT-q)PCR assay.ResultsThe results revealed that CD276 was highly expressed, and was often associated with poorer survival and prognosis, in the majority of different types of cancer. In addition, CD276 expression was found to be closely associated with T cell infiltration, immune checkpoint genes and immunoregulatory interactions between lymphoid and a non-lymphoid cell. It was also shown that the CD276 expression network exerts a wide influence on the immune activation of GBM. The expression of CD276 was found to be positively correlated with neutrophil-mediated immunity, although it was negatively correlated with the level of neurotransmitters, neurotransmitter transport and the regulation of neuropeptide signaling pathways in GBM. It is noteworthy that CD276 expression was found to be significantly higher in GBM compared with normal controls according to the RT-qPCR analysis, and the co-expression network, biological function and chemotherapeutic drug sensitivity of CD276 in GBM were further explored. In conclusion, the findings of the present study have revealed that CD276 is strongly expressed and associated with poor prognosis in most types of cancer, including GBM, and its expression is strongly associated with T-cell infiltration, immune checkpoint genes, and immunomodulatory interactions between lymphocytes and non-lymphoid cells.ConclusionsTaken together, based on our systematic analysis, our findings have revealed important roles for CD276 in different types of cancers, especially GBM, and CD276 may potentially serve as a biomarker for cancer.

【 授权许可】

CC BY   
© The Author(s) 2023

【 图 表 】

Fig. 1

Fig. 4

12888_2022_4500_Article_IEq3.gif

Fig. 10

41116_2022_35_Article_IEq655.gif

Fig. 46

41116_2022_35_Article_IEq599.gif

Fig. 43

41116_2022_35_Article_IEq576.gif

41116_2022_35_Article_IEq569.gif

41116_2022_35_Article_IEq539.gif

41116_2022_35_Article_IEq529.gif

41116_2022_35_Article_IEq520.gif

Fig. 28